GLP-1s and the ‘Wild West’ of Wellness

Summary of GLP-1s and the ‘Wild West’ of Wellness

by New York Times Opinion

1h 14m•May 8, 2026
Listen to Episode

Overview of GLP-1s and the “Wild West” of Wellness

This episode of The Ezra Klein Show examines the rapid rise of GLP-1 drugs like Ozempic, Wegovy, Zepbound, and the experimental retatrutide, and what they mean medically, socially, and culturally. Ezra Klein and Julia Belluz discuss why roughly 1 in 8 Americans may now be taking a GLP-1, how these drugs work, why they are producing effects beyond weight loss, and why they sit at the center of a larger “wellness optimization” boom shaped by social media, telemedicine, and distrust of institutions.

Core Takeaways

  • GLP-1s are more than weight-loss drugs.

    • They were first developed for diabetes, where they help lower blood sugar safely by stimulating insulin only when blood sugar is high.
    • They also appear to affect appetite, inflammation, cardiovascular risk, kidney and liver health, sleep apnea, and possibly addiction-related behaviors.

  • The weight-loss effect is major and often durable only while taking the drug.

    • Typical weight loss ranges from 15% to 30%, depending on the drug and dose.
    • People generally regain weight after stopping because appetite returns.

  • The public response has been surprisingly enthusiastic.

    • In a New York Times poll, 63% of GLP-1 users said they’d want to keep taking the drug even if it didn’t help with weight loss.
    • Many users report unexpected benefits: less “food noise,” fewer cravings, and reduced desire for alcohol, cigarettes, shopping, or other compulsive behaviors.

  • The science is promising but incomplete.

    • Researchers do not fully understand why GLP-1s help with so many conditions.
    • Some benefits appear weight-independent, especially for cardiovascular disease and inflammation.
    • Other areas, like dementia/Alzheimer’s prevention and addiction treatment, remain unresolved or mixed.

How GLP-1s Work

Appetite, the Brain, and “Food Noise”

  • Belluz emphasizes that hunger is not just stomach-driven; it is largely controlled by the brain.
  • GLP-1s mimic a natural hormone and act on brain circuits that regulate appetite and satiety.
  • The drugs seem to make the brain act as if it is receiving a “toxicity” signal, which:
    • reduces appetite,
    • increases nausea in some people,
    • and turns down food cravings.

Why Some People Lose Weight and Others Don’t

  • Response varies widely.
  • There may be genetic differences in sensitivity.
  • Some people feel powerful appetite suppression at low doses; others are relatively insensitive.

Benefits and Medical Promise

Clear Medical Uses

  • Diabetes: safer glucose control with lower risk of dangerous low blood sugar compared with some older approaches.
  • Obesity: first truly effective medical alternative to bariatric surgery for many patients.
  • Cardiovascular risk: trials found about a 20% reduction in cardiac events, which is substantial.
  • Other potential benefits: kidney protection, fatty liver improvement, sleep apnea treatment, and possible effects on inflammation.

The “Three Buckets” of Benefit

Belluz describes the emerging model as three mechanisms:

  1. Weight loss
  2. Reduced inflammation
  3. Direct effects on organs like the liver and kidneys

Risks, Side Effects, and Unknowns

Common Side Effects

  • Nausea
  • Vomiting
  • Diarrhea
  • General GI distress

Emerging Concerns

  • Rare but serious issues are being litigated, including:
    • severe stomach problems,
    • possible optic nerve/eye damage,
    • and other complications not yet fully understood.

The Big Catch: You Usually Have to Stay on Them

  • Many people assume they can use GLP-1s briefly, then stop after learning new habits.
  • In practice, the appetite suppression fades when the drug stops, and weight often returns.

Mental and Emotional Effects

  • Ezra describes his own experience with tirzepatide as revelatory: hunger and desire simply disappeared.
  • But he also felt depressed and anhedonic, raising the question of whether GLP-1s may blunt more than just food cravings for some people.
  • Belluz notes anecdotal reports of changes in reward behavior and mood, especially when people are also on SSRIs or other medications.

Cultural and Social Implications

A New Era of Body Pressure

  • The episode argues that GLP-1s may intensify already punishing body standards.
  • Concerns include:
    • pressure on women and girls,
    • rising appearance culture among boys and men,
    • and the possibility that celebrities/influencers normalize extreme thinness.

Children and Adolescents

  • The most alarming frontier, according to Belluz, is pediatric prescribing.
  • There is little screening for eating disorders in young people taking GLP-1s.
  • The long-term impact on:
    • growth,
    • puberty,
    • muscle and bone development,
    • and body image is not well understood.

From “Fat Acceptance” to Risk-Based Thinking

  • The conversation suggests the old binary — fat-phobic vs. fat-accepting — is giving way to a more complicated view.
  • Many people in body-positivity and fat-acceptance spaces are now wrestling with:
    • the real stigma of obesity,
    • but also the real health risks associated with excess weight.

Wellness, Biohacking, and the “Wild West”

The Blockbuster Drug Meets Algorithmic Culture

  • GLP-1s arrived at the perfect moment for social-media virality:
    • before-and-after photos,
    • telemedicine access,
    • influencer endorsements,
    • and a booming self-experimentation culture.
  • This has fueled a wild west of:
    • compounded medications,
    • research peptides,
    • unregulated online sellers,
    • and people chasing the next optimization hack.

Distrust of Institutions

  • The episode highlights a strange mix:
    • skepticism toward FDA/public health authorities,
    • but eagerness to buy unproven compounds anyway.
  • Belluz frames this as part of a broader post-pandemic shift toward self-directed health decision-making.

The Wellness Industry’s Incentives

  • Podcasts and influencers need novelty, which creates a bias toward the “next new thing.”
  • Sound advice is often boring:
    • sleep more,
    • eat vegetables,
    • move your body,
    • reduce stress.
  • But boring advice doesn’t generate clicks.

Policy and Food Environment

The Real Structural Problem

  • Belluz argues that many chronic diseases are preventable and tied to the food environment:
    • ultra-processed food,
    • junk food marketing to children,
    • poor access to healthy food,
    • and environments that make exercise and sleep harder.

Why Simple Fixes Haven’t Worked

  • The episode is skeptical that small interventions alone will solve the problem.
  • Food deserts, grocery-store access, and marginal tweaks are not enough.
  • Real change would require:
    • stronger regulation,
    • better school food,
    • limits on junk food advertising,
    • and making healthy choices easier than unhealthy ones.

Political Reality

  • The hosts note that Americans are highly sensitive to paternalism.
  • Even when politicians talk about diet-related disease, they often stop short of actually changing the food system.

Recommended Books Mentioned

Julia Belluz’s Influential Reads

  • Behave — Robert Sapolsky
  • Poison Squad — Deborah Blum
  • Ultra-Processed People — Chris van Tulleken

Bottom Line

The episode’s central argument is that GLP-1s are not just a medical breakthrough; they are a window into how deeply biology, environment, and culture shape appetite, health, and desire. They may be transformative for diabetes, obesity, and possibly other chronic conditions, but they also expose how little we understand about the body, how easily a promising drug can become a wellness craze, and how urgently society needs to address the food environment that makes these drugs so attractive in the first place.